News
Blujepa approved by US FDA for treatment of uncomplicated urinary tract infections
The US Food and Drug Administration (FDA) has approved GSK's Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12...
AstraZeneca to invest $2.5bn in global strategic R&D centre, biotech agreements and manufacturing in...
AstraZeneca is to invest $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manufacturing agreements that...
Dupixent approved as first biologic medicine in Japan for patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Sanofi and Regeneron's Dupixent (dupilumab) for the treatment...
